68results about How to "Inhibit progress" patented technology

The invention discloses a medicine for treating osteoarthritis, and belongs to the field of medicine, the medicine comprises a reagent capable of stimulating chondrocyte development, and the medicine L-arginine can promote expression of chondrocyte anabolic factors and reduce expression of cartilage degradation markers, so that chondrocytes are protected to a certain extent; in addition, the medicine provided by the invention has an excellent cartilage repair function, can inhibit the progress of degenerative osteoarthritis, has good biocompatibility, and has no cytotoxicity to cartilage cells.

The invention discloses a GelMA hydrogel composite material as well as a preparation method and application thereof, and belongs to the technical field of material preparation. A micro-needle-shaped GelMA hydrogel composite material (GelMA MNs) is prepared by grafting an anhydride functional group of methacrylic anhydride to a side chain amino group of gelatin, then doxorubicin and an aPD-L1 inhibitor are loaded into the GelMA MNs, a double-drug delivery system is established, and the prepared aPD-L1 / DoxatGelMA MNs can reduce skin injury to the maximum extent, and meanwhile, the aPD-L1 / DoxatGelMA MNs have a good application prospect. Recognition and killing of immune cells on melanoma cells are greatly started, immunogenic cell death (ICD) is promoted, and a new thought is provided for overcoming limitation of ICIs.

The invention discloses an antigen peptide polymer vesicle tumor vaccine as well as a preparation method and application thereof. The antigen peptide polymer vesicle tumor vaccine is obtained by assembling and cross-linking a polymer pre-grafted with antigen peptide and a block polymer and loading an immunologic adjuvant through electrostatic interaction. The vesicle system disclosed by the invention has the advantages of small size, simplicity and controllability in preparation, excellent biocompatibility, high in-vivo circulation stability, targeting of main immune organs, intracellular delivery of antigen peptides and the like. The vesicle nano vaccine displaying the antigen peptide on the surface and encapsulating the immunologic adjuvant can promote dendritic cell maturation and antigen presentation, improve the specific response of mice to tumor-associated antigens, effectively inhibit tumor growth, remarkably prolong the lifetime of tumor-bearing mice and induce a strong immune protection effect, and is high in safety and easy to popularize. A multifunctional'ready-to-use 'nano vaccine concept is embodied, a flexible platform is provided, and different peptide antigens and / or adjuvants can be used for treating different cancers.

The invention discloses a traditional Chinese medicine effective component compound preparation for inhibiting colorectal cancer transformation, which is composed of palmatine, berberine, coptisine and aesculin, and the mass ratio of the palmatine to the berberine to the coptisine to the aesculin is 3: 3: 1: 3. The traditional Chinese medicine active ingredient compound preparation can be prepared into clinical common preparations including granules, capsules or oral liquid according to a conventional method. The traditional Chinese medicine effective component compound preparation disclosed by the invention is proved to be capable of inhibiting intestinal inflammation, improving the intestinal barrier function and remarkably inhibiting colorectal tumor in an inflammatory state by intervening a mouse DSS induced chronic colitis model and an AOM / DSS combined induced colitis and proctitis cancer transformation model.

The invention provides an application of chimeric SFT2D2-TBX19 in diagnosis and treatment of prostatic cancer, and particularly relates to an application of the chimeric SFT2D2-TBX19 as a marker in diagnosis and treatment of prostatic cancer. The nucleotide sequence of the chimeric SFT2D2-TBX19 disclosed by the invention is as shown in SEQ ID NO.1. The overexpression of the chimeric SFT2D2-TBX19 promotes the proliferation, migration and invasion of prostate cancer cells; the chimeric SFT2D2-TBX19 is used for encoding the TBX19-202 protein, the TBX19-202 protein encoded by the chimeric SFT2D2-TBX19 has a carcinogenic effect similar to that of a parent TBX19 in the aspect of promoting the progress of prostatic cancer, and the amino acid sequence of the TBX19-202 protein is shown as SEQ ID NO. 4. Specific high expression of the chimeric SFT2D2-TBX19 in a neuroendocrine prostate cancer (NEPC) cell line is found for the first time, and a new target spot is provided for diagnosis and treatment of related diseases, so that a clinician is guided to provide a prevention method or a treatment scheme for a subject.

The invention provides a USP9X protein allosteric activator T7150 and application of the USP9X protein allosteric activator T7150. It is found for the first time that T7150 induces allosteric deubiquitination enzyme USP9X, enhances the activity of the deubiquitination enzyme USP9X, meanwhile, it is found that T7150 inhibits absorption of macrophages to ox-LDL and reduces formation of foam cells, it is indicated that T7150 can prevent formation of foam cells, and therefore T7150 can be used for inhibiting the progress of atherosclerotic plates. On the other hand, the invention also finds that the T7150 obviously reduces lipid deposition in atherosclerotic plaques and obviously reduces the lipid content in the plaques, which also shows that the T7150 can effectively inhibit the progress of atherosclerosis.

The invention discloses a biaryl compound with necroptosis resisting activity as well as a derivative and application of the biaryl compound. The biaryl compound is a compound as shown in # imgabs0 # or a pharmaceutically acceptable salt of the biaryl compound. The synthesis method of the compound is simple, and the obtained compound can inhibit in-vitro necrotic apoptosis of HT-29 cells and can relieve hepatic fibrosis progress of a schistosome infected mouse model. The compound can be used for preparing drugs for treating and / or preventing inflammatory, fibrosis, infectious, ischemic, degenerative or tumor diseases caused by necrotic apoptosis, and has a good market prospect.

The invention relates to application of LRG1 in preparation of a medicine for promoting differentiation of macrophages to M1 type and a macrophage activator. The invention finds that the LRG1 activates the macrophages and induces the macrophages to differentiate to the pro-inflammatory M1 type, so that the LRG1 is a new inducible factor activated by the macrophages. The invention provides a new mechanism for macrophage activation, and provides a new target spot and thought for preventing and treating inflammatory reaction and inflammatory reaction related diseases and tumors.

The invention belongs to the technical field of medicines and disease treatment, and particularly relates to application of a substance for inhibiting expression of an oxytocin receptor in preparation of a medicine for treating liver cancer. The amino acid sequence of the oxytocin receptor is as shown in SEQ ID NO. 1. By reducing the expression of the oxytocin receptor, it is found that proliferation and migration of the cells can be well inhibited. Through an in-vivo nude mouse tumor-bearing experimental model, the result also shows that the in-vivo proliferation ability of liver cancer cells can be obviously weakened by inhibiting the oxytocin receptor OXTR. Cell experiments, animal experiments and clinical sample analysis prove that the oxytocin antagonist atosiban can significantly inhibit the progress of liver cancer cells.

A multi-mode interaction intelligent ward system comprises a voice recognition module, a touch screen module, a gesture recognition module, a face recognition module, a natural language processing module, a computer vision module, a sensor fusion module, a data encryption and access control module and an emotion recognition module. The system also supports a plurality of input modes such as touch, gesture and face recognition, so that the patients with language barrier or mobility difficulty can conveniently interact with the system, the user groups are greatly expanded, and the universality and usability of the system are improved.

The invention relates to the field of biological medicines, and discloses a preparation method and application of a neutralizing antibody capable of effectively inhibiting dryness of gallbladder cancer cells and progress of gallbladder cancer and remarkably improving the lifetime and prognosis of a patient. A gene sequence for coding the humanized anti-FZD6 monoclonal neutralizing antibody comprises a sequence of a heavy chain variable region and a sequence of a light chain variable region. The gene sequence of the heavy chain variable region is as shown in SEQ ID NO: 1, and the gene sequence of the light chain variable region is as shown in SEQ ID NO: 2. The neutralizing antibody targets a non-classical Wnt pathway receptor FZD6, so that the activation of a Wnt / Ca < 2 + > signal pathway can be effectively inhibited, and the migration and growth of gallbladder tumor cells can be inhibited. Experimental detection proves that the FZD6 neutralizing antibody can effectively block the interaction between Wnt5a-FZD6-mediated tumor-related fibroblasts and gallbladder cancer cells, remodel the gallbladder cancer immunosuppressive tumor microenvironment and inhibit the dryness of gallbladder tumor cells and the migration and growth of gallbladder cancer cells, and can be applied to preparation of gallbladder cancer specific targeting drugs.

The invention belongs to the technical field of traditional Chinese medicine, and particularly discloses a traditional Chinese medicine composition for treating fibromyalgia syndrome and a preparation method and application thereof.The traditional Chinese medicine composition is prepared from radix polygoni multiflori preparata, fructus citri sarcodactylis, radix pseudostellariae, caulis spatholobi, flos rosae rugosae, rhizoma dioscoreae, semen lablab album, rhizoma curcumae longae, lucid ganoderma, arillus longan, flos albiziae and fructus ziziphi jujubae. The traditional Chinese medicine has the effects of soothing liver and strengthening spleen, nourishing and activating blood, calming heart and tranquilizing mind, and activating meridians Pharmacodynamic experiment research and clinical observation results show that the traditional Chinese medicine composition can significantly relieve pain of patients and improve depressive symptoms, and can be used for treating fibromyalgia syndrome.

This invention discloses the application of a PDLIM2 gene overexpression viral vector in the preparation of drugs for treating podocyte disease, wherein the nucleotide sequence of the PDLIM2 gene is shown in SEQ ID NO:1. This invention is the first to discover and verify the core role of the PDLIM2 gene in podocyte protection, confirming its significant downregulation in DKD and FSGS disease models, and demonstrating through functional experiments that PDLIM2 overexpression can effectively stabilize the podocyte cytoskeleton, inhibit apoptosis, and reduce proteinuria, thus establishing it as a key target gene for the treatment of podocyte disease. This invention is the first to intervene at the gene level in the core link of podocyte damage—cytoskeleton stability. By specifically upregulating the expression of PDLIM2 in podocytes, it directly enhances their intrinsic cytoskeleton support and anti-damage ability, achieving a fundamental shift in treatment strategy from "symptomatic support" to "causal repair."

The invention belongs to the technical field of biomedicine, and particularly relates to a bionic T cell secreting type engineering bacterium lung targeted delivery system based on respiratory tract atomization and a construction method and application. The delivery system comprises engineering bacteria and a coated bionic biological membrane, the coated bionic biological membrane is a T cell membrane, and the engineering bacteria can secrete IL-12. The delivery system disclosed by the invention can realize intelligent, precise, visual and non-invasive efficient delivery of exogenous engineering bacteria drugs; by utilizing a gradient freeze-drying technology and an advanced aerosol inhalation technology, local delivery of an exogenous engineering bacterium drug in a host lung is realized, and focus targeted colonization of the engineering bacterium drug is realized; by utilizing an accurate cell membrane coating technology, monitoring and killing of immune cells are reduced, and the colonization efficiency of engineering bacteria is improved; and an engineering bacterium secretion system after biological modification and optimization is synthesized, so that the space-time accuracy of immune regulation of an exogenous engineering bacterium medicine can be further realized in a synergistic manner.

The invention belongs to the technical field of medicines, and relates to a liver cancer targeting extracellular microvesicle as well as a preparation method and application thereof. According to the invention, the extracellular small vesicles are modified by using the small molecule GPC3 nucleic acid aptamer, so that the targeting property of the vesicles to liver cancer tissues can be obviously improved. Due to the improvement of the targeting property, the extracellular small vesicles can more effectively load the anti-tumor drugs and deliver the anti-tumor drugs to the liver cancer cells, so that the accurate and efficient anti-tumor effect is exerted, and the selection of the GPC3 nucleic acid aptamer is based on the high affinity of the GPC3 nucleic acid aptamer and the GPC3 receptors on the surfaces of the liver cancer cells, so that the drugs can be specifically combined with the liver cancer cells.

Provided are a composition for treatment and the like of bovine papillomatosis caused by bovine papillomavirus, and a method using the same. Provided are a composition for treatment, amelioration, and / or suppressing the progression of bovine papillomatosis caused by bovine papillomavirus, the composition containing, as an active ingredient, a compound represented by Formula (I) below or a pharmaceutically acceptable salt of the compound; and a method for treating, ameliorating, and / or suppressing progression of, bovine papillomatosis caused by bovine papillomavirus, the method including administering, to a cow, a compound represented by Formula (I) below or a pharmaceutically acceptable salt of the compound:

The invention discloses an application of paclitaxel in preparation of an anti-breast cancer drug. The invention proposes and verifies that taxafen effectively down-regulates WDYHV1 protein expression of tamoxifen drug-resistant breast cancer cells and induces ferroptosis of cancer cells for the first time, so that the activity of tamoxifen drug-resistant tumor cells is remarkably reduced, the development of breast cancer is inhibited, and a new direction is provided for treatment of tamoxifen drug-resistant lung cancer.

The invention belongs to the technical field of biological medicine, and provides application of clostridium pralaense in preparation of medicine for treating ankylosing spondylitis. According to the application disclosed by the invention, an AS animal model is combined to determine that the F.prausnitzi can prevent the AS progress; experiments find that after intragastric intervention is performed on the AS mouse with the clostridium pralaense, the AS intestinal flora tends to be balanced, the level of inflammatory factors in AS bodies is reduced, inflammatory damage to peripheral joints and spines of the AS mouse is relieved, and the progress of AS model mouse diseases is inhibited, so that a new strategy can be provided for AS treatment through targeted regulation and control of the intestinal flora homeostasis by the clostridium pralaense. In combination with experimental exploration, the following conclusion is drawn: F.prausnitzii can regulate and control the homeostasis of intestinal flora and inhibit the in-vivo inflammatory response of AS, so that the progress of AS is prevented, and the purpose of treating AS is achieved.

The present invention discloses a BP-PEI@RNA nano-drug complex, a preparation method and its application in treating cancer. The BP-PEI@RNA nano-drug complex is composed of RNA and BP modified by PEI. The nano-drug complex can achieve efficient and stable delivery of RNA, transport exogenous gene drugs (RNA) into tumor cells, and inhibit the progression of prostate cancer by increasing the expression level of tumor suppressor genes in tumor cells, and has good clinical application prospects.

The utility model relates to an adjustable toe pad, and relates to the technical field of nursing materials. The utility model discloses a toe correcting device which comprises a bottom pad and a plurality of correcting sleeves, the correcting sleeves are all located on the same side of the bottom pad, a plurality of correcting holes are formed in the bottom pad in a penetrating mode, the correcting holes and the correcting sleeves are arranged at intervals in an arc shape in the direction of toes, the two ends of any correcting sleeve penetrate through the corresponding correcting holes respectively, and the correcting sleeves are detachably connected with the bottom pad. Firstly, a foot is placed on the bottom pad, then toes are put into the corresponding correction sleeves, the correction sleeves are detachably connected with the bottom pad, wearing and dismounting are facilitated, and the installation number of the correction sleeves and the installation distance between the two ends of the correction sleeves can be adjusted according to the actual situation of a user; the correcting sleeve separates the toes from one another, so that toe seams are kept in a breathable state, sweat stains can be effectively absorbed, sweating, secretion generation and adhesion of the toe seams are reduced, and occurrence and development of diabetic feet can be effectively prevented and delayed.

This invention belongs to the field of novel carbon nanomaterials technology, and discloses a Clostridium butyricum-derived carbon dot boat-shaped nanoparticle, its preparation method, and its application. The preparation method includes the following steps: Step 1, Clostridium butyricum is cultured to the logarithmic growth phase, and then placed in a pretreatment solution for suspension incubation to regulate the structural integrity and surface chemical composition of Clostridium butyricum cells. The pretreatment solution is an aqueous solution of EDTA, NaCl, or PEG-8000. After incubation, the precipitate is collected by centrifugation, washed, and resuspended in ultrapure water; Step 2, the Clostridium butyricum treated in Step 1 is placed in a high-pressure reactor for hydrothermal reaction to obtain a crude product system; Step 3, the crude product system is filtered and purified, and freeze-dried to obtain Clostridium butyricum-derived carbon dot boat-shaped nanoparticles. The nanoparticles prepared by this invention have uniform particle size, good water solubility, dispersibility, and biocompatibility, and exhibit significant immunomodulatory functions.

The invention relates to the technical field of biological medicines, and discloses an application of a composition of Tazofelone and taxus medicines in treatment of solid tumors. According to the application disclosed by the invention, the condition that the combination of the Tazofelone and the paclitaxel medicines can be used for treating the generic solid tumors is proposed for the first time, and the tumor killing effect of the low-concentration paclitaxel medicines can be obviously improved by the Tazofelone. The PTCs model is used for simulating the tumor microenvironment, and the drug screening result and the clinical result have high correlation. According to the invention, a plurality of solid tumor PTC models are constructed, and the effects of singly using Tazofelone and jointly using Tazofelone and paclitaxel on inhibiting the progress of the generic solid tumor are detected by detecting the area of PTCs, the ATP content and other indexes. Results show that the development of various solid tumors can be effectively inhibited when the Tazofelone is combined with the paclitaxel, the Tazofelone can obviously enhance the effect of the paclitaxel, the dosage of the paclitaxel can be properly reduced during clinical use, and adverse reactions are reduced while the development of the tumors is effectively inhibited, so that the Tazofelone and the paclitaxel have great application potential clinically.

The invention discloses a micromolecular drug targeting ELF1 and application of the micromolecular drug in intervertebral disc degeneration, and belongs to the technical field of biological medicine, it is found for the first time that the micromolecular compound Mycopherolate Mofetin has a treatment effect on intervertebral disc degeneration, in-vivo and in-vitro verification experiments show that the micromolecular compound Mycopherolate Mofetin has a remarkable inhibition effect on senescence of nucleus pulposus cells, and the micromolecular drug can be used for treating intervertebral disc degeneration. According to the present invention, the application of the Mycopherate Mofetil in the treatment of intervertebral disc degeneration is provided, the progress of intervertebral disc degeneration is significantly inhibited, the new method and the new idea are provided for the clinical treatment of intervertebral disc degeneration, and the significant significance in the adjuvant treatment and prevention of intervertebral disc degeneration is provided, such that the small molecule compound Mycopherate Mofetil has the good clinical application prospect.

The invention belongs to the technical field of biological medicines, and particularly relates to application of an mTOR inhibitor to improvement of sleep disorders. Aiming at the defects of the existing hypnotics, the invention finds that the sleep disorder can be improved by using the Rapamycin through researching a new sleep pathway target. The Rapamycin disclosed by the invention is a non-addictive sleeping drug, and can induce natural sleep behaviors; compared with an existing clinical hypnotics which has the side effect of greatly increasing the death rate, the Rapamycin administration disclosed by the invention is beneficial to improving the sleep quality and prolonging the life of animals at the same time. The invention discloses a remarkable effect of Rapamycin in the aspect of improving the sleep disorder, and the discovery has important significance in improving the sleep quality of a patient and preventing the progress of diseases, so that the Rapamycin has a wide medical prospect and a remarkable economic value.

The invention discloses a biological bionic hybrid membrane coated Prussian blue nano-enzyme, which comprises a Prussian blue nano-enzyme and a neutral granulocyte membrane (N)-macrophage membrane (M) hybrid membrane (NM hybrid membrane), and the Prussian blue (PB) nano-enzyme is coated in the NM hybrid membrane. Compared with an N-PB nano-enzyme and an M-PB nano-enzyme, the hybrid membrane NM-PB nano-enzyme is remarkably improved in the aspects of targeting force and ulcerative colitis treatment.

The invention discloses a bionic high-expression glycosidase exosome system for treating fatty liver-related liver cancer based on glucose metabolism and a preparation method thereof, a glycosidase sequence is transfected to mesenchymal stem cells through lentivirus transfection, and then exosomes are obtained through an ultracentrifugation method for treating the fatty liver-related liver cancer. The exosome bionic system disclosed by the invention has targeted migration capability and low immunogenicity, improves the capability of transporting bioactive substances, normalizes interrupted glucose metabolism, reduces endoplasmic reticulum stress and inhibits epithelial-mesenchymal transition signal transduction. In-vivo and in-vitro experiments prove that the compound can effectively target cancer cells in vitro, reduce abnormal modification of O-GlcNAc and inhibit malignant behaviors of tumors; after reaching the fatty liver related liver cancer in vivo, the compound can reduce the O-GlcNAc modification level and recover damaged metabolism, thereby inhibiting the progress of cancer.

Provided is a pharmaceutical composition for treatment of mucopolysaccharidosis type I patients. Here, the patient has a disorder particularly in the central nervous system. A pharmaceutical composition containing, as an active ingredient, a fusion protein of an anti-human transferrin receptor antibody and human α-L-iduronidase is administered to a patient with mucopolysaccharidosis type I by intravenous infusion at a dose of 0.1 to 10 mg / kg body weight. The administration is performed continually for at least 3 months at intervals of 5 days to 21 days. This decomposes dermatan sulfate and heparan sulfate accumulated in the tissues of the patient, particularly in the central nervous system.

The present invention discloses a user vision protection supervision method and related equipment, which relates to the field of equipment control, and is mainly used to solve the problem that students currently lack relevant eye protection knowledge or lack self-awareness when reading and writing, and it is difficult for them to maintain good reading and writing habits, resulting in a rapid decline in students' vision and difficulty in maintaining vision. The method includes: obtaining target user feature information; predicting specific pressure monitoring thresholds associated with different desk states of users based on the target user feature information; obtaining the desk pressure of the target user; and supervising the desk behavior of the target user based on the desk pressure of the target user and the specific pressure monitoring threshold.

The invention discloses application of a core sequence FAM99Bcore and GalNAc-FAM99Bcore, which are used for combining FAM99B with DDX21 and promoting cutting and degradation of the DDX21, in treatment of liver cancer. The GalNAc-FAM99Bcore can be used for effectively inhibiting the in-vivo progress and metastasis of the nude mouse liver orthotopic xenograft tumor, and has a very high clinical transformation value and a very high market prospect.

The invention relates to the technical field of medicines, in particular to application of PTX3 protein in auxiliary diagnosis and treatment of ovarian cancer peritoneal metastasis. Immunohistochemical experiments show that the expression of PTX3 in peritoneal metastasis tissue is obviously higher than that of primary tumor tissue, and the high expression of PTX3 is in positive correlation with clinical staging and metastasis conditions of patients. Through overexpression and knock-down experiments of PTX3, the overexpression of PTX3 significantly promotes the proliferation, migration and invasion ability of ovarian cancer cells, and the knock-down of PTX3 significantly inhibits the proliferation, migration and invasion ability of ovarian cancer cells. In-vitro experiments comprehensively verify the key effect of PTX3 in ovarian cancer peritoneal metastasis, the importance of PTX3 as a diagnosis and treatment target is defined, and a scientific basis is provided for formulation of clinical diagnosis and treatment schemes.